Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

abstract：:Searching for biomarkers that associated with the acquired resistance of malignant cells to epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies is crucial to improve the clinical benefits of these therapeutic agents. We have recently demonstrated that molecular alterations in both oncogenic and imm...

journal_title：Oncoimmunology

authors： Garrido G,Rabasa A,Sánchez B

更新日期：2013-12-01 00:00:00

abstract：:Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological toler...

journal_title：Oncoimmunology

authors： Vacchelli E,Vitale I,Eggermont A,Fridman WH,Fučíková J,Cremer I,Galon J,Tartour E,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2013-10-01 00:00:00

abstract：:Human γδ T cells possess broad antitumor reactivity and are involved in the control of viral infections. We have recently described multifunctional γδ T cells induced by cytomegalovirus after allogenic stem cell transplantation, placing γδ T cells and their receptors in the spotlight for the development of novel antic...

journal_title：Oncoimmunology

authors： Scheper W,Gründer C,Kuball J

更新日期：2013-05-01 00:00:00

abstract：:Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20-40% of patients to generate anti-tumor immune responses. Combination treatment approaches with chemotherapeutic drugs may enable responses in the remaining patient cohorts. In this regard, a handful of ...

journal_title：Oncoimmunology

authors： Bauzon M,Drake PM,Barfield RM,Cornali BM,Rupniewski I,Rabuka D

更新日期：2019-01-22 00:00:00

abstract：:Innate immunity serves as a first line of defense against infectious agents, and germ-line-encoded pattern recognition receptors detect stressed and infected cells and elicit potent effector activities that accomplish efficient microbe containment. Recent evidence demonstrates that these pattern-sensing systems are al...

journal_title：Oncoimmunology

authors： Jinushi M

更新日期：2012-03-01 00:00:00

abstract：:The advent of immune checkpoint blockade as a new strategy for immunotherapy has changed the outlook for many aggressive cancers. Although complete tumor eradication is attainable in some cases, durable clinical responses are observed only in a small fraction of patients, underlining urgent need for improvement. We pr...

journal_title：Oncoimmunology

authors： Ekiz HA,Lai SA,Gundlapalli H,Haroun F,Williams MA,Welm AL

更新日期：2018-07-11 00:00:00

abstract：:Immune suppression is recognized as a hallmark of cancer and this notion is largely based on studies on cellular immunity. Our recent studies have demonstrated a potential new mechanism of cancer suppression of immunity by impairment of antibody effector function mediated by proteolytic enzymes in the tumor microenvir...

journal_title：Oncoimmunology

authors： Zhang N,Jordan RE,An Z

更新日期：2015-12-29 00:00:00

abstract：:NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results h...

journal_title：Oncoimmunology

authors： Lai JP,Rosenberg AZ,Miettinen MM,Lee CC

更新日期：2012-11-01 00:00:00

abstract：:PD-L1 expression and regulation by mesenchymal tumor cells remain largely undefined. Here, we report that among different EMT-activated MCF7 human breast cancer cell clones, PD-L1 was differentially upregulated in MCF7 sh-WISP2, MCF7-1001/2101, and MDA-MB-231 cells but not in MCF7 SNAI1 and MCF7 SNAI1-6SA cells. Mecha...

journal_title：Oncoimmunology

authors： Noman MZ,Janji B,Abdou A,Hasmim M,Terry S,Tan TZ,Mami-Chouaib F,Thiery JP,Chouaib S

更新日期：2017-01-23 00:00:00

abstract：BACKGROUND:Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. METHODS:Retrospective analysis of 48 stage IV melanoma ...

journal_title：Oncoimmunology

authors： Boudewijns S,Koornstra RH,Westdorp H,Schreibelt G,van den Eertwegh AJ,Geukes Foppen MH,Haanen JB,de Vries IJ,Figdor CG,Bol KF,Gerritsen WR

更新日期：2016-06-17 00:00:00

abstract：:Although the proteasome inhibitor bortezomib has significantly improved the survival of patients with multiple myeloma (MM), the disease remains fatal as most patients eventually develop progressive disease. Recent data indicate that MM cells can evade bortezomib-induced cell death by undergoing autophagy as a consequ...

journal_title：Oncoimmunology

authors： Carlsten M,Namazi A,Reger R,Levy E,Berg M,St Hilaire C,Childs RW

更新日期：2018-11-02 00:00:00

abstract：:LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as ...

journal_title：Oncoimmunology

authors： Nestvold J,Wang MY,Camilio KA,Zinöcker S,Tjelle TE,Lindberg A,Haug BE,Kvalheim G,Sveinbjørnsson B,Rekdal Ø

更新日期：2017-06-16 00:00:00

abstract：:Dietary interventions have a profound impact on whole body metabolism, including oncometabolism (the metabolic features allowing cancer cells to proliferate) and immunometabolism (the catabolic and anabolic reactions that regulate immune responses). Recent preclinical studies demonstrated that multiple dietary changes...

journal_title：Oncoimmunology

authors： Lévesque S,Pol JG,Ferrere G,Galluzzi L,Zitvogel L,Kroemer G

更新日期：2019-04-03 00:00:00

abstract：:The first study demonstrating that human colorectal carcinoma (CRC) is under robust immunosurveillance was published a decade ago. Today, it is clear that CRC patients with Stage III lesions abundantly infiltrated by effector memory T cells have a better prognosis than subjects with Stage I neoplasms exhibiting no or ...

journal_title：Oncoimmunology

authors： Kroemer G,Galluzzi L,Zitvogel L,Fridman WH

更新日期：2015-06-05 00:00:00

abstract：:This proof-of-concept single-arm open-label phase I clinical trial (NCT02481934) studied the safety and efficacy of multiple infusions of activated and expanded natural killer (NKAE) cells in combination with anti-myeloma drugs in multiple myeloma patients. It included five patients with relapsed or refractory MM who ...

journal_title：Oncoimmunology

authors： Leivas A,Perez-Martinez A,Blanchard MJ,Martín-Clavero E,Fernández L,Lahuerta JJ,Martinez-Lopez J

更新日期：2016-11-22 00:00:00

abstract：:Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment. Using two mouse models (RET transgenic melanoma and Panc02 orthotopic pancreatic adenocarcinoma), we identified an elevated frequency of ectonucleotidase-expr...

journal_title：Oncoimmunology

authors： Shevchenko I,Mathes A,Groth C,Karakhanova S,Müller V,Utikal J,Werner J,Bazhin AV,Umansky V

更新日期：2020-04-09 00:00:00

abstract：:Th2-type inflammation has been proposed to facilitate tumor growth. In De Monte et al. (J Exp Med 208:469-478, 2011) we identify in pancreatic cancer a complex cytokine/chemokine cross-talk within the tumor microenvironment mediating Th2 immune-deviation and show that the ratio of Th2/Th1 tumor infiltrating lymphocyte...

journal_title：Oncoimmunology

authors： Protti MP,De Monte L

更新日期：2012-01-01 00:00:00

abstract：:Interleukin-10 (IL-10) is a potent immunomodulatory cytokine, whose cellular targets have not yet been precisely identified. Dendritic cell (DC)-specific IL-10 receptor knockout mice exhibit exaggerated T-cell reactivation in the skin, highlighting a key role of DCs in the maintenance of local immune homeostasis, beyo...

journal_title：Oncoimmunology

authors： Clausen BE,Girard-Madoux MJ

更新日期：2013-03-01 00:00:00

abstract：:The correlation between tumor-infiltrating lymphocyte (TIL)-expression of programmed cell death ligand 1 (PD-L1) and clinical responsiveness to the PD-1 blocking antibody nivolumab implicates adaptive immune evasion mechanisms in cancer. We review our findings that tumor cell PD-L1 expression is induced by interferon ...

journal_title：Oncoimmunology

authors： Kim YJ

更新日期：2015-01-07 00:00:00

abstract：:Esophageal cancer-related gene 4 (Ecrg4), a hormone-like peptide, is thought to be a tumor suppressor, however, little is known about the mechanism of how Ecrg4 suppresses tumorigenesis. Here, we show that the ecrg4 null glioma-initiating cell (GIC) line, which was generated from neural stem cells of ecrg4 knockout (K...

journal_title：Oncoimmunology

authors： Moriguchi T,Kaneumi S,Takeda S,Enomoto K,Mishra SK,Miki T,Koshimizu U,Kitamura H,Kondo T

更新日期：2016-10-14 00:00:00

abstract：:Donor lymphocyte infusion (DLI) is an established and potentially curative immune therapy for relapsed leukemia after hematopoietic stem cell transplant (HSCT). Herein, we describe the utility of DLI as a tractable model system to glean fresh insights into understanding and predicting effective anti-leukemia immunity....

journal_title：Oncoimmunology

authors： Bachireddy P,Wu CJ

更新日期：2014-03-17 00:00:00

abstract：:Recent studies on the processes that lead to the development of pancreatic cancer indicate that inflammatory macrophages have key functions in the initiation of pre-neoplastic lesions. Specifically, acquisition of an activating Kras mutation in pancreatic acinar cells leads to upregulation of intercellular adhesion mo...

journal_title：Oncoimmunology

authors： Storz P

更新日期：2015-03-19 00:00:00

abstract：:Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunothera...

journal_title：Oncoimmunology

authors： Kierkels GJ,Straetemans T,de Witte MA,Kuball J

更新日期：2015-08-27 00:00:00

abstract：:Programmed cell death protein 1 (PD-1) immune checkpoint inhibitors have shown activity in patients with advanced renal cell carcinoma (RCC). However, the role of PD-1 expression in tumor-infiltrating lymphocytes (TILs) as a biomarker for poor outcome is not clear. In this study, we evaluated the prognostic value of T...

journal_title：Oncoimmunology

authors： Kim KS,Sekar RR,Patil D,Dimarco MA,Kissick HT,Bilen MA,Osunkoya AO,Master VA

更新日期：2018-01-10 00:00:00

abstract：:Tumor infiltrating lymphocytes (TIL) in Epstein-Barr virus (EBV)-associated/microsatellite-unstable (MSI) gastric carcinomas (GC) constitute immune-active principal cellular components of tumor microenvironment and contribute to better prognosis. With the remarkable success of cancer immunotherapies, there is an urgen...

journal_title：Oncoimmunology

authors： Park C,Cho J,Lee J,Kang SY,An JY,Choi MG,Lee JH,Sohn TS,Bae JM,Kim S,Kim ST,Park SH,Park JO,Kang WK,Sohn I,Jung SH,Kang MS,Kim KM

更新日期：2017-08-10 00:00:00

abstract：:Neutrophil extracellular traps (NETs) are part of the innate immune defense against microbes, but their contribution to several non-infectious inflammatory conditions has recently been unraveled. We demonstrate that NETs accumulate in the peripheral circulation in tumor-bearing mice, causing systemic inflammation and ...

journal_title：Oncoimmunology

authors： Cedervall J,Dimberg A,Olsson AK

更新日期：2015-10-29 00:00:00

abstract：:Agonistic tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-receptor-specific antibodies are attractive antitumor therapeutics. Recently, our group has generated several human monoclonal antibodies (mAbs) to TRAIL-receptor-1 (TRAIL-R1) (TR1-IgGs) using ISAAC technology. However, these TR1-IgGs did ...

journal_title：Oncoimmunology

authors： Piao X,Ozawa T,Hamana H,Shitaoka K,Jin A,Kishi H,Muraguchi A

更新日期：2016-05-04 00:00:00

abstract：:The persistence of leukemic stem cells (LSCs) in acute myeloid leukemia (AML) patients receiving chemotherapy may be responsible for the high frequency of relapse. The selective elimination of CD96+ AML-LSCs by means of CD96-specific monoclonal antibodies may be a promising therapeutic approach and revitalize autologo...

journal_title：Oncoimmunology

authors： Staudinger M,Humpe A,Gramatzki M

更新日期：2013-06-01 00:00:00

abstract：:Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively correlate with patient...

journal_title：Oncoimmunology

authors： Maas RJ,Hoogstad-van Evert JS,Van der Meer JM,Mekers V,Rezaeifard S,Korman AJ,de Jonge PK,Cany J,Woestenenk R,Schaap NP,Massuger LF,Jansen JH,Hobo W,Dolstra H

更新日期：2020-11-08 00:00:00

abstract：:The immune microenvironment in follicular lymphoma (FL) plays an important role in controlling disease characteristics. To characterize the T-cell receptor (TCR) repertoire in follicular lymphoma (FL) tissues, we applied a next-generation sequencing platform and deeply sequenced TCR cDNAs of T-cell subset populations ...

journal_title：Oncoimmunology

authors： Liu X,Venkataraman G,Lin J,Kiyotani K,Smith S,Montoya M,Nakamura Y,Kline J

更新日期：2015-02-03 00:00:00